AroCell receives a Notice of Allowance for a European patent application

AroCell announces today that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) for the patent application No. 19 163 949.1 and entitled “Monoclonal anti-TK1 antibodies“.

The patent application relates to AroCells proprietary monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. These antibodies are used in the AroCell TK 210 ELISA kit.

“We are thrilled that we have got a Notice of Allowance in Europe for this patent application. This means that the chance is high for the patent to be granted in the near future. This will reinforce our patent position in Europe and increase AroCells attractiveness as a business partner. We will continue to develop our portfolio of proprietary assets to further expand its business opportunities and to support our product AroCell TK 210 ELISA,” says Michael Brobjer, CEO AroCell.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com